17.03.2020 19:20:00

Sartorius Stedim Biotech Postpones Annual Shareholders' Meeting

AUBAGNE, France, March 17, 2020 /PRNewswire/ -- Sartorius Stedim Biotech S.A. will postpone its Annual General Shareholders' Meeting formerly scheduled for March 24, 2020, to a later date due to the coronavirus pandemic and the associated restrictions imposed on travel and meetings. This was resolved today by the Board of Directors of the company. 

 

 

As a result of the cancelation of the Annual General Shareholders' Meeting on March 24, 2020, the vote on the resolution on the assignment of the financial result for the year ended December 31, 2019, and the payment of dividends, among other things, will also be deferred.

The 2020 Annual General Shareholders' Meeting is to be scheduled for a new date within six months after the close of the fiscal year ending on December 31, 2019 as provided for under the French Commercial Law. Sartorius Stedim Biotech will inform its shareholders and the public in a timely manner about its further planning. 

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2019, the company employed approx. 6,200 people, and earned sales revenue of €1,440.6 million according to preliminary figures.

Follow Sartorius on Twitter @Sartorius_Group and on LinkedIn. 

Contact:
Petra Kirchhoff  
Head of Corporate Communications and Investor Relations
+49 (0)551.308.1686 
petra.kirchhoff@sartorius.com      
www.sartorius.com  

 

Cision View original content:http://www.prnewswire.com/news-releases/sartorius-stedim-biotech-postpones-annual-shareholders-meeting-301025703.html

SOURCE Sartorius Stedim Biotech S.A

Analysen zu Sartorius Stedim Biotechmehr Analysen

22.10.24 Sartorius Stedim Biotech Neutral UBS AG
17.10.24 Sartorius Stedim Biotech Buy Goldman Sachs Group Inc.
03.10.24 Sartorius Stedim Biotech Buy Goldman Sachs Group Inc.
03.10.24 Sartorius Stedim Biotech Neutral UBS AG
02.09.24 Sartorius Stedim Biotech Outperform RBC Capital Markets
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Sartorius Stedim Biotech 179,60 -1,37% Sartorius Stedim Biotech